Discovery Laboratories could see the end of its struggle to launch
its Surfaxin (lucinactant) drug on the US market as it has finally
resolved the manufacturing issues that have plagued the product for
Laureate Pharma is planning to invest up to $9m (€7.1m) to expand
its biopharmaceutical manufacturing facility in New Jersey with a
new pilot production plant, as it seeks more capacity to cope with
increased demand from clients for...